Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract

Latest news

04 May, 2021
Pneumagen are attending the 21st BioEquity Europe Global Digital Event
08 Mar, 2021
Pneumagen Announces Neumifilâ„¢ is Efficacious In an Established Model of COVID-19 Infection
21 Jan, 2021
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year

Meet the team